Madrigal Pharmaceuticals Inc (MDGL)

[DMOST]

Best ETFs for 2018: ALPS Medical Breakthroughs ETF Keeps Rolling Along

Of note:

Another example of a second quarter SBIO star is Madrigal Pharmaceuticals (NASDAQ:MDGL). The stock saw some profit-taking in late June, but that is to be expected when a stock enters the final trading day of a month with an intra-month gain of over 150%.

In a single trading day in early June, Madrigal cobbled together the bulk of its monthly gains, more than doubling after revealing positive Phase II clinical trial results for its treatment of nonalcoholic steatohepatitis, or NASH.

The stock rallied later in the month on news Madrigal may be exploring a sale, a logical move given the potentially lucrative nature of the NASH market and the desire for large-cap biotechnology and pharmaceuticals companies to gain easy access to that arena.

Madrigal is 2.65% of SBIO’s weight as of Jun. 28.

https://finance.yahoo.com/news/best-etfs-2018-alps-medical-192323242.html

GO MDGL

"PEACE"